현재 가격
$1008.27
경쟁 해자
↑Patent Protection on Key Drugs
Lilly benefits from strong patent protection on drugs like Trulicity and Mounjaro. This exclusivity allows for premium pricing and market share dominance before generics enter.
↑Established Brand Reputation in Diabetes Care
Lilly has cultivated a strong brand in diabetes, fostering physician and patient loyalty. This reputation provides a competitive edge in a growing market.
↑Pipeline of Innovative Therapies
Lilly's robust pipeline, particularly in Alzheimer's and obesity, offers future growth potential. Successful drug launches will further solidify their market position.
투자 리스크
↓Patent Expirations and Generic Competition
Loss of exclusivity on key drugs will significantly impact revenue. Lilly must successfully launch new products to offset these losses and maintain growth.
↓Clinical Trial Failures and Regulatory Hurdles
Drug development is inherently risky, and clinical trial failures are common. Regulatory delays or rejections can significantly impact pipeline value.
↓Pricing Pressure and Reimbursement Challenges
Increasing pressure from payers to lower drug prices could erode profitability. Changes in reimbursement policies could limit access to Lilly's therapies.
AI 인사이트를 DCF 또는 PE 주식 밸류에이션과 결합하여 내재가치를 계산하세요. 데이터에 기반한 더 나은 주식 밸류에이션 결정을 내리세요.
본 페이지는 Eli Lilly and Company (LLY)에 대한 AI 기반 주식 밸류에이션 인사이트를 경쟁 해자와 투자 리스크 요인을 포함하여 제공합니다. 주식 밸류에이션은 건전한 투자 결정의 핵심입니다 — MiniValuator의 DCF 및 PE 주식 밸류에이션 도구를 이러한 AI 인사이트와 함께 사용하여 LLY의 내재가치, 안전마진을 계산하고 근거 있는 주식 밸류에이션 판단을 내리세요.
